{"id":2131,"date":"2006-12-01T12:03:00","date_gmt":"2006-12-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/vasopressin-rezeptor-antagonisten-bei-vasopressin-vermittelter-hyponatriaemie"},"modified":"2006-12-01T12:03:00","modified_gmt":"2006-12-01T11:03:00","slug":"vasopressin-rezeptor-antagonisten-bei-vasopressin-vermittelter-hyponatriaemie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/vasopressin-rezeptor-antagonisten-bei-vasopressin-vermittelter-hyponatriaemie","title":{"rendered":"Vasopressin-Rezeptor-Antagonisten bei Vasopressin-vermittelter Hyponatri\u00e4mie"},"content":{"rendered":"<p>Bei schwerer Herzinsuffizienz (NYHA 4) und bei dekompensierter hydropischer Leberzirrhose entwickelt sich oft eine mitunter schwere Hyponatri\u00e4mie, die durch ein intrazellul\u00e4res Hirn\u00f6dem zu Krankheitsgef\u00fchl, Konfusion und eventuell zu zerebralen Krampfanf\u00e4llen f\u00fchren kann. Die pathophysiologische Ursache ist bei beiden Krankheiten eine \u201earterielle Volumen-Unterf\u00fcllung\u201d mit Tendenz zur arteriellen Hypotonie, wodurch die Sekretion von Arginin-Vasopressin (AVP, antidiuretisches Hormon [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bei schwerer Herzinsuffizienz (NYHA 4) und bei dekompensierter hydropischer Leberzirrhose entwickelt sich oft eine mitunter schwere Hyponatri\u00e4mie, die durch ein intrazellul\u00e4res Hirn\u00f6dem zu Krankheitsgef\u00fchl, Konfusion und eventuell zu zerebralen Krampfanf\u00e4llen f\u00fchren kann. Die pathophysiologische Ursache ist bei beiden Krankheiten eine \u201earterielle Volumen-Unterf\u00fcllung\u201d mit Tendenz zur arteriellen Hypotonie, wodurch die Sekretion von Arginin-Vasopressin (AVP, antidiuretisches Hormon [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[4304,4303,180,3059,3952,4305,4302,3055,3054,3056,3057,3639,531,4301],"class_list":["post-2131","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antidiuretisches-hormon","tag-conivaptan","tag-herzinsuffizienz","tag-hyponatriaemie","tag-leberzirrhose","tag-lixivaptan","tag-salt-studie","tag-schwartz-bartter-syndrom","tag-siadh","tag-syndrom-der-inadaequaten-adh-sekretion","tag-syndrom-der-inappropiaten-adh-sekretion","tag-tolvaptan","tag-vasopressin","tag-vasopressinrezeptor-antagonisten"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2131"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2131\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}